Amicus Therapeutics Receives Positive CHMP Opinion for Opfolda® (miglustat) for Late-Onset Pompe Disease
26 avr. 2023 13h00 HE
|
Amicus Therapeutics, Inc.
European Commission Approval of Opfolda and Commercial Launch of Pombiliti® + Opfolda® Anticipated in 3Q 2023 Upon Approval, Pombiliti + Opfolda will be the First Two-Component Therapy in the...
Amicus Therapeutics Announces European Commission Approval for Pombiliti™ in Patients with Late-Onset Pompe Disease
27 mars 2023 07h00 HE
|
Amicus Therapeutics, Inc.
Approved as a Long-Term Enzyme Replacement Therapy in Combination with Miglustat for All Adults Living with Late-Onset Pompe Disease CHMP Opinion for Miglustat, the Oral Enzyme Stabilizer Component...
Amicus Therapeutics Announces Full-Year 2022 Financial Results and Corporate Updates
01 mars 2023 07h00 HE
|
Amicus Therapeutics, Inc.
2022 Revenue Growth of 16% at CER to $329M Projecting Galafold Revenue Growth in 2023 of 12-17% at CER U.S. FDA Pre-approval Inspection for AT-GAA Now Scheduled; Approval expected in 3Q 2023 EU and...
Amicus Therapeutics to Present at the Cowen 43rd Annual Health Care Conference
27 févr. 2023 07h00 HE
|
Amicus Therapeutics, Inc.
PHILADELPHIA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Cowen 43rd Annual Health Care Conference...
Amicus Therapeutics Announces Positive Long-Term Data from Phase 3 Open-label Extension Study of AT-GAA in Late-Onset Pompe Disease at the 19th Annual WORLDSymposium™ 2023
22 févr. 2023 17h00 HE
|
Amicus Therapeutics, Inc.
Meaningful and Durable Responses in Key Endpoints of Six-Minute Walk, Forced Vital Capacity for ERT-Naïve and ERT-Experienced Participants Out to Two Years Consistent Reduction in Biomarkers Continue...
Amicus Therapeutics to Announce Full-Year 2022 Financial Results on March 1, 2023
14 févr. 2023 07h00 HE
|
Amicus Therapeutics, Inc.
PHILADELPHIA, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, March 1, 2023 at...
Amicus Therapeutics Announces Presentations and Posters at the 19th Annual WORLDSymposium™ 2023
13 févr. 2023 07h00 HE
|
Amicus Therapeutics, Inc.
PHILADELPHIA, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that two oral presentations and 11 posters across its development programs will be included at the...
Amicus Therapeutics to Present at the SVB Securities Global Biopharma Conference
08 févr. 2023 07h00 HE
|
Amicus Therapeutics, Inc.
PHILADELPHIA, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the SVB Securities Global Biopharma...
Amicus Therapeutics Reports Preliminary 2022 Revenue and Provides 2023 Strategic Outlook
09 janv. 2023 07h00 HE
|
Amicus Therapeutics, Inc.
Significant Growth in Demand with More Than 2,000 People Living with Fabry Disease on Galafold by End of 2022 2022 Full Year Revenue of ~$329M, Representing 16% YoY Growth at CER Continued...
Amicus Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
03 janv. 2023 07h00 HE
|
Amicus Therapeutics, Inc.
PHILADELPHIA, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that Bradley Campbell, President and Chief Executive Officer, will present at the 41st Annual J.P....